WE.SPEED.
WE AIM TO SPEED UP PATIENTS' ACCESS TO INNOVATIVE THERAPIES BY COLLABORATING WITH CUTTING-EDGE PHARMACEUTICAL COMPANIES.

FACTS

14 CLINICS In 8 countries in Europe,
North America and Africa MORE...
15 TO 60 DAYS Fast start-up/regulatory
timelines MORE...
5 TO 30-FOLD Patient enrollment
vs competition MORE...
9 TO 24 MONTHS PROOF-OF-CONCEPT MORE...

DISRUPTIVE ADDED VALUE

UNIQUE APPROACH TO EVALUATE EFFICACY OF NOVEL THERAPEUTICS IN RECORD TIME

Timely access to new therapies is critical for patients, providing them with better treatment options and potentially life-saving solutions. The pharmaceutical industry faces pressure to develop new therapies rapidly and efficiently while maintaining data safety and quality.

ARENSIA’s playing field

The PROOF OF CONCEPT phase, particularly the "first-in-patient" clinical trials (Phase IB or IIA), is critical in the drug development process. It detects the initial efficacy signal of new therapies (compounds) in the targeted patient population. Data from these trials determine whether to continue or halt research of the respective new compound before significant investments in later phases of drug development.

Industry challenge

The demand for advanced Phase I/II PROOF OF CONCEPT clinical trials requires specialized research personnel and facilities. However, traditional clinical trial sites often lack these resources, prompting pharmaceutical companies to involve multiple sites for trials, resulting in high costs and delays for protocols with low patient numbers (12-200).

ARENSIA solution

At ARENSIA, we have addressed industry needs by establishing a proprietary network of research clinics in 8 countries over the past decade, spanning various therapeutic areas.

All ARENSIA Clinics are exclusively dedicated to expediting PROOF OF CONCEPT trials, ensuring the highest safety standards for patients and data quality.

Typical clinical trial sites encounter challenges like overcrowded schedules, insufficient staff, and prolonged contract negotiations. In contrast, ARENSIA Clinics achieve significant time reductions through unparalleled recruiting performance. By concentrating efforts on a select number of ARENSIA's research-dedicated clinics instead of a high number of clinical trial sites, we achieve a significant budget reduction for Phase IB/IIA PROOF-OF-CONCEPT trials.

Our 93% repeat business underscores that ARENSIA delivers a disruptive breakthrough in time and cost, fostering continuous growth and collaborations with leading pharmaceutical companies, biotechs, and global CROs.

WATCH THIS VIDEO Find out more about us in 2 minutes

WHAT OUR SPONSORS SAID

In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.

Leading Global Pharmaceutical Company, US based

We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.

Mid-Size Biotech Company, US based

We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.

Leading Global CRO, US based

NEWS

ARENSIA DOSES FIRST PATIENT IN GROUNDBREAKING HEPATITIS B GENE EDITING TRIAL ARENSIA DOSES FIRST PATIENT IN GROUNDBREAKING HEPATITIS B GENE EDITING TRIAL 13.03.2025

ARENSIA DOSES FIRST PATIENT IN GROUNDBREAKING HEPATITIS B GENE EDITING TRIAL ARENSIA Research Clinic is proud to announce that we have dosed the wo...

READ MORE
HAPPY HOLIDAYS! HAPPY HOLIDAYS! 20.12.2024

Reflecting on 2024, we are deeply grateful for your research endeavors and trust. Your innovation and support have driven our growth and inspired us t...

READ MORE
FIRST PATIENT SUCCESSFULLY DOSED IN PHASE 1 STUDY FOR NCFB IN KYIV, UKRAINE FIRST PATIENT SUCCESSFULLY DOSED IN PHASE 1 STUDY FOR NCFB IN KYIV, UKRAINE 07.11.2024

We are thrilled to announce that ARENSIA’s clinic in Ukraine has successfully dosed the very first patient in an advanced Phase 1 study for Non-...

READ MORE
ARENSIA IS SET TO LAUNCH THE WORLD`S FIRST GENE EDITING TRIAL FOR HEPATITIS B VIRUS (HBV)! ARENSIA IS SET TO LAUNCH THE WORLD`S FIRST GENE EDITING TRIAL FOR HEPATITIS B VIRUS (HBV)! 04.11.2024

With over a decade of specialized expertise in conducting sophisticated Phase IB and II trials, including pioneering first-in-class and best-in-class ...

READ MORE
ARENSIA CLINIC IN PHOENIX DRIVES RAPID PATIENT RECRUITMENT FOR EARLY-PHASE CLINICAL TRIALS ARENSIA CLINIC IN PHOENIX DRIVES RAPID PATIENT RECRUITMENT FOR EARLY-PHASE CLINICAL TRIALS 23.09.2024

Since its launch last year, ARENSIA’s Research Clinic in Phoenix, Arizona, has made remarkable progress, playing a pivotal role in Phase IB and ...

READ MORE
ARENSIA HAS SIGNIFICANTLY EXPEDITED A PHASE IB TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS ARENSIA HAS SIGNIFICANTLY EXPEDITED A PHASE IB TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS 24.06.2024

In Ukraine alone, rare diseases like IPF affect 10-15 people out of 100.000 population, typically diagnosed in individuals over 40. Without treatment,...

READ MORE
ARENSIA ENROLLS FIRST PATIENT WORLDWIDE IN COMPLEX MULTIPLE SCLEROSIS STUDY! ARENSIA ENROLLS FIRST PATIENT WORLDWIDE IN COMPLEX MULTIPLE SCLEROSIS STUDY! 19.03.2024

We love being in the lead! ARENSIA has once again achieved a significant milestone by enrolling the first patient globally, this time in a complex mul...

READ MORE
CONTACT US

This website uses cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about the traffic in our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. Detailed information about the use of necessary cookies, which are essential to browse this website, and optional cookies, which you can select below, and how you can review or withdraw your consent at any time can be found in our Privacy Statement.

Always ON Essentials

Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

  • cookiePreference

    This essential functionality ensures that your choices regarding data privacy and personalization are respected and consistently applied during your visits. You can seamlessly navigate our website with the confidence that your selected settings are in place, providing a tailored and secure user experience.

    Expiry: 1 year Type: Local
  • cookiePreference-*

    This cookie is an advanced component of our website, meticulously designed to track and manage the specific categories of cookies you allow. This innovative functionality ensures that your customized cookie settings are precisely implemented, offering a seamless and personalized browsing experience that aligns with your privacy preferences.

    Expiry: 1 year Type: Local
Statistics

Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.

  • Google Analytics

    We create pseudonymous user profiles with the help of Google Analytics in order to design our websites in line with requirements. Google Analytics uses targeting cookies that are stored on your end device and can be read by us. In this way, we are able to recognize and count returning visitors and find out how often our websites are accessed by different users. Data processing is carried out on the basis of Art. 6 para. 1 lit. a) GDPR (consent) and § 25 para. 1 TDDDG. The information generated by the cookie about your use of our website is usually transmitted to a Google server in the USA and stored there. However, since we have activated IP anonymization on our website, your IP address will be shortened by Google beforehand within member states of the European Union. Only in exceptional cases will the full IP address be transmitted to a Google server in the USA and only shortened there (further information on the purpose and scope of data collection can be found, for example, at https://policies.google.com/privacy?hl=de&gl=de). We have also concluded an order processing contract with Google LLC (USA) in accordance with Art. 28 GDPR. Google will therefore only use all information strictly for the purpose of evaluating the use of our websites for us and compiling reports on website activity.

    _ga_

    This cookie is used by Google Analytics to persist session state.

    Expiry: 1 year 1 month Type: Third-party
    _ga

    This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports.

    Expiry: 1 year 1 month Type: Third-party
  • Hotjar

    We use Hotjar Observe, a service provided by Hotjar Ltd, 3 Lyons Range, 20 Bisazza Street, Sliema SLM 1640, Malta, on our website. This is a software for the analysis and optimization of online offers on the basis of pseudonymous measurements and analyses of user behavior, which may include in particular A/B tests (measurement of the popularity and user-friendliness of different content and functions), measurement of click paths and interaction with content and functions of the online offer (so-called heat maps and recordings). The legal basis is your consent in accordance with Art. 6 para. 1 lit. a) GDPR and Section 25 para. 1 TDDDG.

    _hjSessionUser_*

    Set when a user first lands on a page. Ensures data from subsequent visits to the same site are attributed to the same user ID. Persists the Hotjar User ID which is unique to that site. Hotjar does not track users across different sites.

    Expiry: 1 year Type: Third-party
    _hjSession_*

    Holds current session data. Ensures subsequent requests in the session window are attributed to the same session.

    Expiry: 1 hour Type: Third-party
  • Zoom Info

    We use the advertising services of ZoomInfo for our website. The service provider is the Canadian company ZoomInfo Technologies LLC, 805 Broadway, Suite 900, Vancouver, WA 98660, Canada. Your data may also be processed in Canada and thus outside the scope of the GDPR. The European Commission has decided that there is an adequate level of protection for commercial offers from Canada in accordance with Art. 45 para. 1 GDPR. This means that data transfer to this country is permitted.

    __cf_bm

    This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.

    Expiry: 30 minutes Type: Third-party
    _zitok

    First-party cookie set by ZoomInfo to identify unique visitors.

    Expiry: 1 year Type: Third-party
    _cfuvid

    The _cfuvid cookie is used to allow the Cloudflare WAF to distinguish individual users who share the same IP address. Visitors who do not provide the cookie are likely to be grouped together and may not be able to access the site if there are many other visitors from the same IP address.

    Expiry: Session Type: Third-party
Marketing

Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

  • Linkedin

    Our website uses the “LinkedIn Insight Tag” conversion tool from LinkedIn Ireland Unlimited Company, Wilton Place, Dublin 2, Ireland.This tool creates a cookie in your web browser, which enables the following data to be collected: IP address, device and browser characteristics and page events (e.g. page views). This data is encrypted, anonymized within seven days and the anonymized data is deleted within 90 days. LinkedIn does not share any personal data with us, but offers anonymized reports on the website target group and display performance. LinkedIn also offers the option of retargeting via the Insight Tag.

    AnalyticsSyncHistory

    Used to store information about the time a sync with the lms_analytics cookie took place for users in the Designated Countries.

    Expiry: 1 month Type: Third-party
    li_gc

    Used to store guest consent to the use of cookies for non-essential purposes

    Expiry: 6 months Type: Third-party
    lidc

    Facilitates data center selection.

    Expiry: 1 day Type: Third-party
    UserMatchHistory

    This cookie is used to track visitors so that more relevant ads can be presented based on the visitor's preferences.

    Expiry: 1 month Type: Third-party
    bscookie

    Used for remembering that a logged in user is verified by two factor authentication and has previously logged in.

    Expiry: 1 year Type: Third-party
    bcookie

    Browser Identifier cookie to uniquely identify devices accessing LinkedIn to detect abuse on the platform .

    Expiry: 1 year Type: Third-party
    li_sugr

    Used to make a probabilistic match of a user's identity.

    Expiry: 3 months Type: Third-party
Allow all Allow selection Deny